A PHASE II STUDY OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH c-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY S1400K, NCT03574753)

INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET positive squamous cell carcinoma (SCC). METHODS: Patients with previously treated SCC with c-MET positive tumors (H score ≥150, Ventana SP4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lung Cancer
Main Authors: Waqar, Saiama N, Redman, Mary W, Arnold, Susanne M, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Gandara, David R, Stinchcombe, Thomas E, Leighl, Natasha B, Ramalingam, Suresh S, Tanna, Saloni H, Raddin, Ryan S, Minichiello, Katherine, Bradley, Jeffrey D, Kelly, Karen, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8044254/
https://ncbi.nlm.nih.gov/pubmed/33221175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2020.09.013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados